Health ConditionsHeavy menstrual bleeding (HMB) can be defined objectively as a total blood loss per menstrual cycle that regularly exceeds 80 mL. This threshold is based on population studies establishing that blood loss above this level is associated with iron deficiency. However, a definition requiring quantification of blood loss is only useful for research studies, and accurate assessment of menstrual blood flow is difficult. For clinical purposes, HMB is defined as excessive menstrual blood loss that interferes with a woman's physical, emotional, social, and material quality of life. Normal menstrual blood loss ranges between 20 and 60 mL per cycle.
Heavy menstrual bleeding is commonly defined as menstrual blood loss exceeding 80 mL of blood loss per cycle, although only about half of women who complain of HMB actually meet these criteria. This discrepancy reflects the fact that women's subjective perception of their flow does not always correspond to measured volume. One population study demonstrated poor correlation between women's perception of and actual menstrual blood loss: 37% and 4% of women with blood loss greater than 80 mL considered their blood loss to be moderate or scanty, respectively; 14% of women with blood loss less than 20 mL considered their blood loss to be heavy.
HMB was historically referred to as menorrhagia. HMB has an estimated prevalence of 18–32% but is known to be under-reported due to poor recognition and estimation of menstrual blood loss. More broadly, up to one-third of women will meet criteria for HMB at some point in their lifetime.
HMB typically presents as one or more of the following: soaking through a pad or tampon every hour or more for several consecutive hours; needing to use double protection (pad and tampon simultaneously); passing blood clots larger than a small coin; or bleeding lasting longer than seven days. The most problematic symptom for women with uterine fibroids, a major cause of HMB, is heavy menstrual bleeding with menstrual periods of increased duration and volume; in some cases menstrual periods can last as long as 10 to 14 days rather than the usual 5 to 7 days, and blood loss can be as high as 300 to 500 mL.
Persistent heavy menstrual bleeding can induce iron-deficiency anemia and associated fatigue and loss of energy. The effects on cognitive function as well as the related work and school absenteeism and presenteeism can undermine the efforts and function of women in all walks of life, be they students, educators, employers, or employees.
HMB is a common gynecological complaint with multiple etiologies and diverse pathophysiological origins. At the tissue level, normal menstruation is initiated by a carefully orchestrated process. The withdrawal of progesterone with luteal regression has been postulated to be the trigger for the initiation of menstrual bleeding, with the induction of stromal shrinkage and spiral arteriolar vasoconstriction with relative hypoxia in the functionalis layer, followed by the instigation of acute inflammatory changes including the influx of large amounts of leucocytes and immune cells, launch of the inflammatory cascade (increase in proinflammatory cytokines, prostaglandins and destructive enzymes of the extracellular matrix such as MMPs exclusively in the endometrial stratum functionalis), and the activation of stem/progenitor cells postulated to be resident in the endometrial stratum basalis.
The shedding of the "old" stratum functionalis usually happens over 1–2 days yet the menstrual bleeding continues during the proliferation and repair of the surface epithelium of the damaged stratum functionalis, which takes several days. When any component of this process is disrupted—including vascular architecture, prostaglandin balance, or endometrial repair mechanisms—excessive bleeding may result. It is currently believed the endometrium's control of arachidonic acid supply for prostaglandin synthesis is altered with menorrhagia.
The coagulation system plays a critical role in limiting menstrual blood loss. The overall prevalence of a laboratory diagnosis of von Willebrand disease in women presenting with HMB has been reported to be as high as 13%. Aetiology is due to underlying uterine pathologies, coagulopathy, ovulation dysfunction, or iatrogenic causes; up to 20% of women with HMB will have an underlying inherited bleeding disorder. Mild platelet function defects are also a frequently found hereditary haemostatic disorder in women with heavy menstrual bleeding.
The hypothalamic-pituitary-ovarian (HPO) axis governs cyclical hormone production that orchestrates endometrial growth and shedding. Ovulatory dysfunction in young adult women is mostly a result of immaturity or temporary/chronic disturbances of the hypothalamic–pituitary–ovarian axis; the temporary or chronic disorder in this axis is associated with androgen excess syndrome (e.g., polycystic ovary syndrome), hypothalamic dysfunction due to eating disorders, weight loss and dieting, obesity, excessive physical exercise, poor nutrition, alcohol and drug abuse, or stress, and thyroid diseases.
Up to one-third of women of reproductive age experience HMB; HMB can give rise to iron deficiency and, in severe cases, iron-deficiency anemia (IDA). This creates a feedback cycle in which ongoing blood loss continuously depletes iron stores faster than dietary intake can replenish them.
HMB is discussed with reference to the recently proposed PALM-COEIN classification system for abnormal uterine bleeding, initially describing the endometrial events in normal menstruation followed by discussion of the perturbations of normal endometrial shedding that can result in HMB. The acronym covers structural causes (Polyp, Adenomyosis, Leiomyoma, Malignancy/hyperplasia) and non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified). A variety of functional, structural, and non-structural conditions can cause HMB, including adenomyosis, leiomyomas, and coagulopathies as well as iatrogenic causes; in many women, the underlying cause of HMB is unknown and is referred to as functional HMB.
Uterine leiomyomas (often referred to as fibroids or myomas) are common benign, estrogen-dependent tumours that grow in the muscular wall of the uterus and occur in approximately 25% of women of reproductive age; while the majority of uterine fibroids are asymptomatic, approximately 25% of women with fibroids develop symptoms requiring treatment. The heavy menstrual bleeding associated with uterine fibroids is likely caused by the increase in surface area of the uterine cavity, poor uterine contraction due to the myoma, and increased circulation, congestion, or impaired haemostasis due to hypertrophy of the endometrium near the myoma. The incidence of uterine fibroids increases as women grow older, and risk factors include nulliparity, obesity, family history, black race, and hypertension.
Obesity in adolescence is associated with greater menstrual cycle irregularity and polycystic ovary syndrome (PCOS), which can result in infrequent or absent menstrual periods, and heavy menstrual bleeding. Research using animal models has shed light on a direct biological mechanism: mice fed a high-fat diet that resulted in weight gain had significantly delayed endometrial repair compared to mice fed a normal diet; the high-fat-diet group also had higher levels of local inflammatory mediators in their uterine tissue following progesterone withdrawal; the researchers concluded that increased body weight can alter endometrial function and result in increased menstrual blood loss.
Hyperandrogenism, higher testosterone and fasting insulin levels, and lower levels of sex hormone-binding globulin, similar to the laboratory findings seen in patients with PCOS, are also seen in individuals with obesity, and help to explain the overlap in phenotype between patients with obesity and those with PCOS.
Hormonal causes of HMB include anovulation and hypothyroidism. One overlapping symptom of both thyroid disease and uterine fibroids is abnormal, heavy menstrual bleeding; this can also lead to fatigue and anemia in both conditions. The thyroid hormones thyroxine (T4) and tri-iodothyronine (T3) influence the production of coagulation factors and the function of the endometrium; hypothyroidism in particular is associated with anovulatory cycles and heavier-than-normal menstrual flow.
Both obesity and PCOS can result in an increased risk of endometrial hyperplasia and cancer due to prolonged endometrial exposure to unopposed estrogen in the setting of chronic anovulation and inadequate progesterone exposure. Prolonged anovulation allows the endometrium to proliferate unopposed, resulting in irregular and often very heavy withdrawal bleeds.
A number of factors that often play a role in the regularity and blood loss of a woman's menstrual cycle include female sex hormone changes, genetics, serious medical conditions, body mass index (BMI), lifestyle, and stress. Relative estrogen dominance — whether from endogenous overproduction, impaired hepatic metabolism, or reduced progesterone output during the luteal phase — is widely discussed in the reproductive medicine literature as a contributor to excessive endometrial proliferation and heavier bleeds, though the precise clinical threshold remains an active area of research.
Hypothalamic dysfunction due to eating disorders, weight loss and dieting, obesity, excessive physical exercise, poor nutrition, alcohol and drug abuse, or stress is associated with disruption of the HPO axis. These disruptions can impair the cyclical progesterone production needed to stabilize the endometrium. Dietary habit and body composition can develop risk of menstrual disorders.
Up to one-third of women of reproductive age experience HMB; HMB can give rise to iron deficiency and, in severe cases, iron-deficiency anemia. HMB associated with iron-deficiency anemia negatively affects quality of life; management of IDA usually begins with oral iron supplementation or, if ineffective or poorly tolerated, intravenous iron is given.
There is an increasing body of evidence suggesting that iron deficiency, even in early pregnancy, may adversely impact fetal neurodevelopment with enduring effects on a spectrum of cognitive and psychological disorders — effects that can have widespread impacts on society.
The widely cited research threshold for dietary iron sufficiency in this population is guided by the WHO definition: iron-deficiency anemia is defined by the World Health Organization (WHO) as a haemoglobin concentration below 12 g/dL (120 g/L) for non-pregnant women.
Multiple clinical guidelines recommend screening all women presenting with HMB for anaemia. Of 22 guidelines included in one systematic review, the majority (16/22) focused on guidance to screen women with HMB for anemia; the guidance varied with respect to identifying symptoms, the criteria for testing, and diagnostic haemoglobin levels.
Traditional and Clinical Context: Iron is not traditionally used to reduce bleeding volume; rather, it is the foremost nutritional repletion priority following blood loss from HMB. It has been used in medicinal iron preparations since the 19th century for anaemia arising from "flooding" (an older term for very heavy periods).
Scientific Evidence: Heavy menstrual bleeding can lead to iron-deficiency anaemia; one study investigated whether daily administration of a formula containing iron, essential amino acids, ascorbic acid, and B-group vitamins for 28 days would increase haemoglobin levels by 0.5 g/dL and reduce menstrual bleeding. This was a single-blind, placebo-controlled clinical trial on 26 anaemic women (Hb <12 g/dL) with heavy menstruation; haemoglobin, iron balance, cell count, and menstrual bleeding were measured after treatment with placebo and the formula. Multiple systematic reviews of clinical guidelines confirm that iron supplementation — oral or, when oral is poorly tolerated, intravenous — remains the cornerstone nutritional intervention for IDA secondary to HMB, though it does not directly reduce bleeding volume. Evidence for iron supplementation in this context is strong and consistent across international guidelines.
Traditional Use: Vitamin C, combined with bioflavonoids (plant-derived polyphenolic compounds found in citrus peel, berries, and buckwheat), has been used in nutritional medicine since the mid-20th century, based on their role in vascular integrity. Bioflavonoids such as rutin were used in naturopathic and eclectic herbal traditions to reduce capillary fragility and control "pathological" uterine bleeding.
Scientific Evidence: Vitamin C, along with bioflavonoids, has been proposed to help reduce heavy bleeding by making capillaries stronger and preventing them from becoming fragile; in one small study with 18 women who had heavy menstrual bleeding, bleeding improved in 16 out of the 18 patients when the women took vitamin C and bioflavonoids. This small, uncontrolled study (n=18) represents weak evidence by modern standards — it lacks a control group and blinding. In addition, vitamin C can also help women who have suffered from iron deficiency from menorrhagia by increasing iron absorbency. Vitamin C's role as an iron absorption enhancer is well-established: it converts ferric iron (Fe³⁺) to the more bioavailable ferrous form (Fe²⁺) in the gastrointestinal tract. This application has stronger evidence than the claimed direct haemostatic effect.
Traditional Use: Vitamin D was not historically used in traditional herbalism or nutritional traditions for heavy periods; its relevance to reproductive physiology has emerged primarily through modern research.
Scientific Evidence: The active form of vitamin D can reduce prostaglandin production in the endometrium and limit its biological activity by affecting prostaglandin receptors; it may also exert anti-inflammatory effects through various pathways. Despite this plausible mechanism, clinical trial evidence to date is not supportive of a blood-loss-reducing effect. In one study, low-dose vitamin D (5,000 IU) had no significant effect on menstrual blood loss; furthermore, high-dose vitamin D (50,000 IU) weekly for nine weeks had no effect on heavy menstrual flow; similarly, one RCT found high doses of vitamin D did not reduce menstrual bleeding in the experimental group. Studies on the impact of vitamin D on menstrual bleeding are limited; future randomized controlled clinical trials with a greater sample size, longer duration of treatment, different doses of vitamin D, and more extended follow-up periods are therefore required to confirm the efficacy of vitamin D in treating menstrual blood loss. Overall, current evidence does not support vitamin D supplementation as an effective intervention for reducing menstrual blood volume.
Traditional Use: Dietary fish oils and flaxseed oil have been used in naturopathic medicine for menstrual irregularity and heavy flow, based on their role in modulating the balance between pro-inflammatory and anti-inflammatory prostaglandins.
Scientific Evidence: The proposed mechanism centres on prostaglandin biology: omega-3 fatty acids from marine sources (EPA and DHA) competitively displace arachidonic acid as a substrate for cyclooxygenase enzymes, shifting prostaglandin production away from the pro-inflammatory, vasodilatory prostaglandin E2 and thromboxane A2 (which increase bleeding) toward less potent series-3 prostaglandins. It appears that omega-3 fatty acids may reduce the psychiatric symptoms of PMS including depression, nervousness, anxiety, and lack of concentration, and may also reduce somatic symptoms of PMS including bloating, headache, and breast tenderness. However, the available RCT evidence is primarily for PMS and dysmenorrhoea, not for measured blood volume in HMB. A broader safety meta-analysis found that omega-3 PUFAs were not associated with increased bleeding risk overall; patients receiving high-dose purified EPA may incur additional bleeding risk, although its clinical significance is very modest. Evidence specifically for omega-3s reducing measured menstrual blood loss in HMB is preliminary and limited.
Traditional Use: Magnesium is used in nutritional medicine for conditions broadly related to the female reproductive cycle, including PMS, dysmenorrhoea, and menstrual irregularity, based on its roles in muscle relaxation, prostaglandin modulation, and nerve function.
Scientific Evidence: Direct evidence from rigorous trials specifically measuring its effect on menstrual blood volume in women with HMB is limited. Magnesium's role in relaxing smooth muscle (potentially reducing painful uterine cramping) and its involvement in the regulation of inflammatory pathways are mechanistically plausible. The evidence base for magnesium supplementation in HMB is weak and largely indirect; no high-quality RCTs have demonstrated a statistically significant reduction in measured blood loss attributable to magnesium supplementation alone.
Traditional Use: Vitamin A deficiency has long been associated with menstrual disorders in traditional nutritional medicine. Early 20th-century clinicians noted that nutritional deficiencies could impair uterine function.
Scientific Evidence: Clotting abnormalities including vitamin K deficiency, and circulating inhibitors of coagulation, are documented causes of HMB. Vitamin A is required for the normal differentiation of endometrial epithelial cells, and early observational studies in populations with widespread vitamin A deficiency found associations with menstrual irregularity. Formal RCT evidence specifically examining vitamin A supplementation for HMB in well-nourished populations remains sparse. The clinical literature does not currently support routine supplementation with vitamin A for HMB in the absence of documented deficiency.
Traditional Use: Ginger has been used for thousands of years across Ayurvedic, Traditional Chinese, and Middle Eastern medicine systems for dysmenorrhoea and to regulate menstrual flow. In Ayurvedic practice it is typically prepared as a decoction of the dried rhizome.
Scientific Evidence: One systematic review aimed to assess the effectiveness and safety of herbal preparations for the treatment of idiopathic HMB; MEDLINE, Ovid, and the Cochrane Central Register were searched from inception to August 2015; only RCTs were considered; three randomized controlled trials were included. In two studies, ginger capsules and myrtle fruit syrup significantly reduced the menstrual duration and blood loss compared with placebo based on the pictorial blood loss assessment chart score (p <0.001, p=0.01). A trial investigating pomegranate flower capsules found they were as effective as tranexamic acid capsules in reducing the mean pictorial blood loss assessment chart score, with no significant difference between the two treatments (p=0.3). While these results are promising, the total number of included trials is small, sample sizes are modest, and further large-scale RCTs are required to confirm efficacy and determine optimal dosing.
Traditional Use: Vitex agnus-castus L. (chaste tree; chasteberry) is a popular herbal treatment, predominantly used for a range of female reproductive conditions in Anglo-American and European practice. Historically documented in European herbal traditions since ancient Greece, it was used to suppress libido in monks (giving rise to the name "chaste tree") and later adopted for menstrual irregularities and PMS. Preparations include dried berry extracts, tinctures, and tablets.
Scientific Evidence: One study suggested that chasteberry might reduce heavy menstrual bleeding related to an intrauterine device (IUD), but the evidence is of low quality. Several studies of low-to-moderate quality in people have evaluated chasteberry for alleviating PMS symptoms such as breast pain or tenderness; there is not a lot of strong research on the effectiveness of chasteberry for other conditions. A 2019 systematic review and meta-analysis examined multiple RCTs specifically evaluating Vitex on menstrual bleeding volume. Based on subgroup analysis, the consumption of Vitex did not have a significant effect on the amount of menstrual bleeding compared to the placebo group in the first (MD: 3.08; 95% CI: −3.11–9.26; p=0.33; I²=0%) and second menstrual cycles. The current weight of evidence does not support Vitex as an effective agent for reducing heavy menstrual blood loss per se, though it may have effects on the broader symptom constellation of PMS. Chasteberry is generally well tolerated in the short term.
Traditional Use: Astringent herbs form a large category of tannin-containing plants used to reduce blood loss from the reproductive tract as well as the gastrointestinal tract, respiratory tract, and skin; in the reproductive tract, astringent herbs are used to correct uterine or cervical bleeding; of these, shepherd's purse has a long history of use in the management of preventing or arresting gynaecologic haemorrhage. The plant is mentioned in European botanical texts dating to the 16th century. It is typically prepared as a tincture (hydroethanolic extract of the fresh aerial parts) or as a tea. In traditional herbal medicine, uterine tone determines the ease of menstrual flow; therefore, if the uterus is hypotonic, there may be heavy bleeding; improving uterine tone may normalize and regulate menstrual bleeding.
Scientific Evidence: As of the most recent literature searches, rigorous human clinical trial evidence specifically for shepherd's purse as a monotherapy in HMB remains very limited. Its constituent flavonoids (including quercetin and luteolin) have demonstrated haemostatic and vasoconstricting properties in preliminary in vitro and animal research, but these findings have not yet been replicated in adequately powered RCTs in humans. It is not included in major systematic reviews of HMB pharmacotherapy due to absence of qualifying trials. Evidence quality is currently insufficient to support definitive clinical recommendations.
Traditional Use: Yarrow has been used in European, First Nations North American, and Chinese herbal medicine as a haemostatic and anti-inflammatory herb for both internal and topical bleeding. In European traditions it was prepared as a tea or tincture of the aerial parts. Its botanical genus name references the Greek hero Achilles, who reportedly used it to staunch soldiers' wounds.
Scientific Evidence: Rigorous clinical trial evidence for yarrow specifically in HMB is currently absent from the peer-reviewed literature. Its traditional use rests on a documented content of achillin and related sesquiterpene lactones, flavonoids, and tannins, which have demonstrated anti-inflammatory and platelet-modifying effects in vitro. No adequately powered RCTs in humans measuring blood volume outcomes are available in the current literature.
Traditional Use: Pomegranate flower and bark have been used in traditional Persian and Ayurvedic medicine for uterine bleeding and gynaecological complaints.
Scientific Evidence: In one RCT, pomegranate flower capsules were as effective as tranexamic acid capsules in reducing the mean pictorial blood loss assessment chart score, with no significant difference between the two treatments (p=0.3). This is a single small trial, and results should be interpreted with caution pending independent replication in larger populations.
Dietary habit and body composition can develop risk of menstrual disorders; the relationship between macronutrient intake, anthropometric indices, and menstrual disorders has been the focus of cross-sectional research. Analysis of cross-sectional findings highlights the importance of the issue that dysmenorrhoea, abnormal bleeding, irregular menstruation, and PMS were worsened by obesity. Diets high in refined carbohydrates and saturated fats that contribute to increased adiposity may therefore indirectly worsen HMB via their effects on body weight and the hormonal environment.
From an iron-absorption standpoint, dietary composition is highly relevant. Vitamin C can enhance the absorption of iron by the gastrointestinal tract; conversely, phytates (in bran), polyphenols (in certain fruits and vegetables), tannins (in tea and coffee), calcium (in dairy), and oxalates (in spinach, beans, and nuts) may inhibit iron absorption. Women with HMB who are iron-depleted benefit from dietary strategies that emphasise iron-rich foods alongside enhancers of iron absorption.
Obesity increases the risk for developing gynaecological diseases including infertility and menstrual dysfunction. Researchers using animal models concluded that increased body weight can alter endometrial function and result in increased menstrual blood loss. Body-weight management, particularly in women with a high BMI, is discussed in the research literature as a strategy that may support more regular and less heavy menstrual cycles through its effects on circulating oestrogen levels, insulin resistance, and HPO axis regulation.
In women with menstrual abnormalities, regular exercise has been demonstrated to reduce menstrual irregularities. A substantial amount of research has indicated that elevated levels of physical activity and modifications to lifestyle habits may serve to mitigate symptoms associated with the menstrual cycle. However, the relationship between exercise and HMB specifically is nuanced: very high levels of exercise (particularly in athletes with low energy availability) can also disrupt the HPO axis and cause anovulatory cycles, which may paradoxically contribute to abnormal bleeding patterns.
Stress plays a role in the regularity and blood loss of a woman's menstrual cycle. Hypothalamic dysfunction due to stress is among the factors associated with disorders of the HPO axis that can produce anovulatory cycles with irregular and heavy bleeds. The precise clinical magnitude of psychosocial stress as an independent contributor to HMB volume, separate from its indirect effects on ovulation, has not been quantified in prospective trials.
Lifestyle factors such as alcohol consumption may also play a role in fibroid development, which is itself a major structural cause of HMB. Alcohol consumption can also affect hepatic oestrogen metabolism; the liver is the primary site of oestrogen conjugation and excretion, and impaired hepatic function may lead to elevated circulating oestrogen levels. However, direct RCT evidence quantifying the effect of alcohol reduction on menstrual blood volume is not currently available in the literature.
The present understanding of the mechanisms of menstrual bleeding as well as many of the pathological aberrations of HMB is incomplete; further research into the pathophysiology of HMB is urgently needed, as clear knowledge of the mechanisms of this disorder will provide new therapeutic targets to formulate more effective treatments. In the nutritional and herbal domain specifically, most studies suffer from small sample sizes, heterogeneous populations, lack of standardised bleeding outcome measures, short follow-up periods, and methodological limitations including inadequate blinding. Until larger, well-controlled RCTs are available, most nutritional and herbal recommendations in this context should be characterised as preliminary or traditional-use-based, rather than evidence-based.
Boswellia serrata oleoresin was evaluated alongside ginger in a 2019 randomized, double-blind, placebo-controlled clinical trial (Eshaghian et al., Complement Ther Med) involving 102 women with heavy menstrual bleeding. Both frankincense and ginger, taken as adjuncts to ibuprofen, significantly reduced bleeding amount and duration and improved quality of life compared to ibuprofen plus placebo. Boswellic acids are thought to inhibit leukotriene and prostaglandin synthesis, reducing uterine inflammation.
Vitex is clinically used in abnormal uterine bleeding disorders, and a large real-world cohort (n=1700) documented significant improvements in bleeding intensity and frequency after three months of VAC treatment. German Commission E approval covers menstrual cycle irregularities, which encompasses heavy or irregular bleeding.
Heavy periods can result from estrogen dominance; DIM shifts estrogen metabolism toward less proliferative metabolites, providing a plausible mechanism. A small RCT in women with endometriosis found that DIM 300 mg/day alongside standard treatment significantly improved bleeding patterns. No dedicated large RCT exists for heavy menstrual bleeding as the primary endpoint.
EGCG, the primary bioactive catechin in green tea, has been shown in a randomized controlled pilot trial to reduce uterine fibroid volume and associated heavy menstrual bleeding. Women with symptomatic fibroids receiving 800 mg/day green tea extract (45% EGCG) for 4 months experienced a 32.6% reduction in fibroid volume and 32.4% reduction in symptom severity including blood loss, compared to placebo. Fibroids are a leading structural cause of heavy periods.
Multiple randomized controlled trials demonstrate that ginger (Zingiber officinale) significantly reduces menstrual blood loss and duration in women with heavy periods. A 2015 placebo-controlled RCT (Kashefi et al., Phytother Res) found 250 mg dried ginger three times daily over three menstrual cycles significantly reduced heavy bleeding measured by pictorial blood loss assessment chart (PBAC). A 2019 RCT also showed ginger enhanced ibuprofen's effectiveness in reducing bleeding duration and improving quality of life.
Iron deficiency and iron-deficiency anemia both result from and can worsen heavy menstrual bleeding, creating a bidirectional cycle. Iron deficiency may weaken uterine muscle contractility, impairing hemostasis. A prospective Finnish study (Peuranpää et al., published in Acta Obstet Gynecol Scand 2014) found 27% of women with heavy periods were anemic and 60% severely iron-deficient, and iron supplementation is recommended to improve quality of life and potentially reduce subsequent bleeding.
TCM formulations containing C. rotundus have demonstrated efficacy in reducing uterine bleeding in clinical use. Network pharmacology supports hemostatic mechanisms through multi-target modulation. Traditional Ayurvedic and TCM use for menorrhagia is also documented.
Menorrhagia is associated with elevated uterine tissue levels of arachidonic acid (omega-6), which drives prostaglandin E2-mediated vasodilation and excessive bleeding. Increasing omega-3 fatty acid intake from fish oil, flaxseed oil, or supplements competitively reduces arachidonic acid levels in uterine tissue, thereby lowering prostaglandin E2 synthesis. ScienceDirect's menorrhagia overview and integrative medicine protocols recommend 1,000–3,000 mg EPA+DHA daily to reduce blood loss.
Punica granatum flower has been used in traditional Iranian medicine for excessive menstrual bleeding. A 2015 double-blind RCT (Goshtasebi et al., MJIRI) in 94 women with heavy menstrual bleeding of endometrial origin found pomegranate flower capsules were as effective as tranexamic acid over three menstrual cycles (no significant difference in PBAC scores, p=0.3). A 2023 triple-blind RCT further confirmed equivalence to tranexamic acid in abnormal uterine bleeding.
Progesterone deficiency—due to anovulation in perimenopause, PCOS, or other causes—allows unopposed estrogen to thicken the endometrial lining, resulting in heavier, longer, and less predictable bleeding. Progestins are a first-line clinical treatment for abnormal uterine bleeding (AUB), with RCT evidence supporting their use for endometrial stabilization.
R. cordifolia is employed in traditional Asian medicine for abnormal uterine bleeding (AUB), with pharmacological studies demonstrating mechanisms including modulation of the coagulation cascade, fibrinolytic system, and COX-2/cPLA2 inhibition. TCM prescriptions containing R. cordifolia are used clinically for AUB. The hemostatic use is also documented in Tibetan and Ayurvedic traditions.
Shepherd's purse (Capsella bursa-pastoris) has been used since antiquity as a hemostatic herb for gynecological hemorrhage. A 2018 triple-blind, placebo-controlled RCT (Naafe et al., J Altern Complement Med) tested 640 mg/day hydroalcoholic extract in 84 women with clinical menorrhagia over two cycles, demonstrating significantly greater PBAC-measured bleeding reduction versus placebo alongside mefenamic acid. It is recognized in the European Pharmacopoeia and described by ESCOP for antihemorrhagic use.
Vitamin A deficiency has been identified as an independent risk factor for heavy menstrual bleeding, with serum retinol levels significantly lower in women with menorrhagia than controls. In a clinical study of 40 women with menorrhagia, vitamin A supplementation produced complete relief or significant reduction in 92.5% of subjects. Vitamin A appears to regulate endometrial proliferation and interacts with estrogen metabolism.
Several studies link vitamin D deficiency to menstrual cycle disorders including heavy bleeding. A 2023 double-blind RCT (Amzajerdi et al., BMC Women's Health) found that a single high-dose vitamin D supplementation significantly reduced menstrual blood loss in young women with primary dysmenorrhea and vitamin D deficiency. Vitamin D also slows fibroid growth, a common cause of menorrhagia, according to a 2023 systematic review.
Agrimony (Agrimonia eupatoria or Agrimonia pilosa) is an ancient astringent wound herb used throughout medieval European and Chinese (Agrimonia pilosa) traditional medicine to stop both internal and external bleeding, including heavy menstrual flow. Its hemostatic activity is attributed to tannins that promote clotting and blood vessel constriction. Direct RCT evidence for menorrhagia is absent; traditional use is well-documented across multiple herbal traditions.
Alchemilla vulgaris (Lady's Mantle) has a long history in European herbal medicine as an astringent remedy for heavy and irregular menstrual bleeding. Its high tannin content is considered responsible for reducing excessive menstrual flow by promoting blood vessel constriction and enhancing clotting. Clinical RCT evidence is limited; its use is categorized as traditional, with pharmacological support from tannin chemistry.
Allspice is listed in traditional herbalism for heavy menstrual bleeding (menorrhagia). Its astringent tannin content is thought to reduce excessive bleeding. The indication is reported in Caribbean and Ayurvedic traditional medicine and in herbal reference databases. No clinical evidence exists.
Amaranth (particularly A. spinosus) has a documented traditional use for menorrhagia (heavy menstrual bleeding) in South Asian folk medicine, specifically in Pakistan. The plant's astringent properties and traditional blood-stopping uses are cited. There are no human clinical trials for this indication.
Bayberry has a traditional use for heavy menstrual bleeding (menorrhagia) and uterine hemorrhage, attributed to its astringent and hemostatic properties. This use appears in 19th-century American herbal texts and several folk medicine compilations. No clinical evidence exists.
Biota seed (and biota leaf, Ce Bai Ye) are used in TCM for heavy or irregular menstrual flow, including hemorrhagic presentations. WebMD (RxList) lists heavy menstrual bleeding (menorrhagia) among the traditional indications for oriental arborvitae, but states there is no good scientific evidence to support this use. Multiple classical TCM herbals document this indication.
Blackberry has a documented history of use in Western European and Native American herbal medicine for heavy menstruation (menorrhagia), attributed to its astringent tannin content which may reduce excessive bleeding. Herbal Reality and other ethnobotanical sources specifically note this traditional application.
Tibetan medicine documents use of broomrape to stop excessive menstrual bleeding. This is cited in classical Tibetan herbal literature within the category of hemostatic applications. No pharmacological or clinical evidence exists for this indication.
Cinnamon bark (Cinnamomum species) has been used in traditional medicine systems including Ayurveda and traditional Chinese medicine as a uterine stimulant and hemostatic agent for heavy menstrual bleeding and uterine disorders. ScienceDirect botanical overviews list cinnamon among the key astringent herbs traditionally employed for menorrhagia. Laboratory evidence supports anti-inflammatory properties, but RCT evidence specifically for menstrual blood loss reduction is limited.
Cornus officinalis is used in TCM for menorrhagia (heavy menstrual periods), attributed to its astringent properties and kidney-tonifying action. This use has been documented in TCM literature for over a millennium. It is commonly used in multi-herb formulas. No human clinical trial data exist.
Dong Quai has a well-documented traditional use in TCM for menorrhagia (heavy menstrual bleeding) and is listed among the principal proposed uses in authoritative herbal databases and the EMA assessment report. Its uterine tonic and hemostatic actions in TCM are complemented by a plausible pharmacological mechanism involving uterine smooth muscle modulation. Clinical trial evidence for Dong Quai monotherapy for heavy periods is lacking.
Geranium has longstanding traditional use as a hemostatic and astringent agent for heavy menstrual flow. This use is documented across multiple traditional medicine systems including African, European, and Asian herbalism. No clinical trials have been conducted.
Goldenseal is used in traditional herbal practice for heavy menstrual bleeding, attributed mainly to hydrastine's hemostatic properties. It appears in Eclectic medical references as a uterine hemostatic, though no clinical trials have evaluated this use.
Horsetail has a documented traditional use as a hemostatic and astringent agent for managing menorrhagia (heavy menstrual bleeding). This use appears in Chinese traditional medicine and in Western herbalism, attributed to its tannin content and hemostatic properties. No clinical trials have evaluated horsetail specifically for this indication.
In TCM, lotus seeds are a classical astringent herb used for heavy menstruation (menorrhagia) attributed to kidney qi deficiency failing to consolidate blood. This use is well-documented in classical texts and materia medica. No modern clinical evidence exists.
Nettle has a long-established traditional use as a hemostatic agent for reducing excessive menstrual flow, documented in ethnobotanical records and herbal monographs across Brazil, Europe, and the Middle East. The astringent tannin content and vitamin K presence provide a pharmacological rationale. No human clinical trials specifically addressing heavy menstrual bleeding as a primary endpoint have been identified.
Platycladi cacumen (dried branches and leaves) is documented in the Chinese Pharmacopoeia and classical TCM texts as a hemostatic herb specifically indicated for dysfunctional uterine bleeding and heavy menstrual flow (menorrhagia). This is one of its primary traditional indications. WebMD/NLM and multiple systematic reviews confirm this use.
In Traditional Chinese Medicine, purslane is classified as having hemostatic properties specifically indicated for metrorrhagia (excessive uterine bleeding). Persian traditional medicine also recommends purslane juice for excessive menstrual flow. No clinical RCTs evaluating purslane for heavy menstrual bleeding were identified.
Raspberry leaf has a well-documented traditional use for heavy menstrual bleeding (menorrhagia) attributed to its astringent tannins, which are believed to tonify and tighten uterine tissue and reduce excessive blood flow. This use appears in European and Native American herbal traditions, as well as in herbalist references such as the Appalachian use of Rubus roots for hemorrhaging. No controlled human trials measuring menstrual flow volume with raspberry leaf have been conducted.
Charred Schizonepeta has been used in TCM for heavy menstrual bleeding (menorrhagia/metrorrhagia) for centuries. The Chinese Pharmacopoeia records this use. Laboratory evidence confirms hemostatic mechanisms. WebMD and RxList list this as a traditional use. No human clinical trials isolating Schizonepeta for menorrhagia have been published.
Root tea made from sheep's sorrel has been traditionally used as a remedy for excessive menstrual bleeding, attributed to its astringent and styptic properties. This use is documented in folk herbal practice. No clinical evidence exists.
Excessive menstrual bleeding (menorrhagia) is a well-documented traditional indication for smartweed across European, South Asian, and East Asian herbal systems. The plant contains vitamin K and rutin, which support coagulation and capillary integrity, providing a mechanistic rationale.
Solomon's seal is documented in late 19th and early 20th century eclectic medical texts and historical European herbals for menorrhagia (heavy menstrual bleeding). The herb's astringent and hemostatic properties underpin this application.
Viburnum species (particularly V. opulus, cramp bark, and V. prunifolium, black haw) have extensive traditional use in North American Eclectic and European herbal medicine for uterine cramping and excessive menstrual bleeding. Cramp bark is listed as containing tannins and antispasmodic constituents (scopoletin, viopudial) that reduce uterine smooth muscle spasm and slow heavy bleeding. In vitro and historical clinical reports support uterine relaxant properties; modern RCTs are lacking.
Vitex agnus-castus (chaste tree/chasteberry) has been used in Greco-Roman and European herbal tradition to regulate menstrual disorders including heavy bleeding, based on its ability to modulate the hypothalamic-pituitary-ovarian axis and reduce prolactin. A 2019 systematic review and meta-analysis of five RCTs found Vitex did not significantly reduce menstrual blood volume versus placebo in controlled trials, though retrospective cohort data show benefits for cycle regularity and abnormal uterine bleeding.
Yarrow (Achillea millefolium) has been used since ancient Greece and throughout European and indigenous North American herbal traditions as a hemostatic herb for heavy menstrual bleeding, named after Achilles who reportedly used it to stop soldiers' wounds. Its tannin content is thought to constrict blood vessels. Modern scientific evidence from RCTs specifically for menorrhagia is lacking, though wound-healing and astringent properties are pharmacologically documented.
Go back